Group 1 - Sanofi has a registered share capital of €2,438,854,192 [1] - As of January 31, 2026, the total number of issued shares is 1,219,502,262 [1] - The number of voting rights excluding treasury shares is 1,341,656,083, while the theoretical number of voting rights including treasury shares is 1,353,618,860 [1] Group 2 - The information regarding shares and voting rights is available on Sanofi's official website under "Regulated Information in France" [2] - The Investor Relations Department can be contacted via email at investor.relations@sanofi.com [2]

Summary of C4 Therapeutics Conference Call Company Overview - C4 Therapeutics is focused on targeted protein degradation (TPD) with a clinical pipeline that includes its lead program, cemsidomide, an IKZF1/3 degrader, which is in later-stage clinical development [6][8] - The company has a phase 2 study called the MOMENTUM trial, which is set to start this quarter, and a phase 1/b study in combination with elranatamab planned for the second quarter [6][8] - C4 has collaborations with Betta Pharmaceuticals for an EGFR degrader in China, and ongoing partnerships with Biogen, Roche, and Merck KGaA [7] Pipeline and Development Focus - Cemsidomide is a key focus, but the company is also excited about its discovery efforts and collaborations [8] - The company plans to evaluate data from the phase 1 study for the EGFR degrader to determine potential U.S. clinical development [8] - The emphasis on discovery collaborations is crucial for the company's strategy [8] Regulatory Environment and MRD Negativity - The FDA's new draft guidance on minimal residual disease (MRD) as a surrogate endpoint for myeloma is seen as beneficial for expediting drug development [10][11] - C4 Therapeutics believes that incorporating MRD negativity as an endpoint can help de-risk drug development and support accelerated approval [11][14] - The company plans to measure MRD negativity in its trials to strengthen the case for cemsidomide's approval [13][14] Competitive Landscape - Upcoming data from Bristol's iberdomide and mezigdomide trials will provide insights into the efficacy of highly potent degraders, which could benefit the field [16][17] - C4 Therapeutics does not view these trials as direct competition but anticipates they will provide benchmark data for planning pivotal trials [17] Clinical Trial Design and Expectations - The company aims for a 40% response rate in the MOMENTUM trial, with a minimum expected response rate of 20% to support accelerated approval [25][24] - The timeline for patient enrollment is set at 12 months, with early readouts expected within a year of closing the study [26][23] - Full regulatory endpoints will require longer follow-up, projected into 2028 [26] Financing and Future Plans - Recent financing has extended the company's runway to the end of 2028, allowing for the execution of planned studies [28] - Additional funding of over $200 million could facilitate a swift transition from phase 1/b to phase 3 planning [28] Combination Studies and Dosing Strategies - The company is designing studies for cemsidomide in combination with elranatamab, focusing on patients with 2 to 4 lines of prior therapy [30] - Dosing strategies are being carefully considered to manage overlapping toxicities and ensure patient safety [34][35] Communication and Updates - C4 Therapeutics commits to providing reasonable top-line updates as the trial progresses, with the first update expected after completing the first cohort [37][39] Conclusion - C4 Therapeutics is strategically positioned in the TPD space with a strong focus on cemsidomide and its potential for accelerated approval through innovative trial designs and regulatory strategies [6][8][10]

CHICAGO, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the expansion of its digital assets program with the purchase of $500,000 of Bitcoin (BTC), underscoring the Company’s disciplined, opportunistic, and flexible approach to capital deployment. The Company’s digital assets program has so far been centered on Ethereum (ETH). While Ethereum will continue to serve as a key pi ...

Core Insights - Eli Lilly has become the largest healthcare company and the first to reach a market capitalization of $1 trillion, outperforming broader equities over the past five years [1] Financial Performance - Eli Lilly reported exceptional financial results, with fourth-quarter sales of $19.3 billion, reflecting a 43% year-over-year increase, and adjusted earnings per share of $7.54, up 42% compared to the previous year [3] - The company anticipates revenue between $80 billion and $83 billion for the current year, indicating a top-line growth of 25% at the midpoint, which exceeds analysts' expectations despite price reductions on key medicines [4] Market Position - Eli Lilly is gaining significant ground in the diabetes and weight management market, with its tirzepatide drug generating over $30 billion in sales in 2025, making it the world's best-selling compound [5] - The company's market share for incretin analogs has increased to 60.5% by the end of 2025, while competitor Novo Nordisk's share has decreased to 39.1%, indicating Lilly's dominance in this sector [6] Pipeline Development - Eli Lilly has several promising pipeline candidates, including an oral GLP-1 medicine, orforglipron, expected to gain approval by the second quarter of 2026, and retatrutide, which has shown excellent phase 3 results targeting weight loss [7]

Core Insights - Novo Nordisk aims to capture approximately 15 million new patients when Medicare begins covering obesity treatments later this year [1][2] - Medicare's coverage is expected to expand the market for obesity medicines and encourage private insurers to follow suit, with estimates suggesting 20 million to 30 million Medicare patients suffer from obesity and related conditions [2] - The company anticipates that Medicare coverage, along with the launch of a new obesity pill, will help increase prescription volumes despite lower prices in the U.S. due to previous agreements [3] Group 1 - Novo Nordisk's CEO indicated that the target of 15 million patients is based on the specific products and target group within the 67 million Americans covered by Medicare [1] - The company is currently negotiating with the government regarding the exact timing of when Medicare coverage will begin [5] - There is a cautious outlook on the immediate impact of Medicare coverage, contrasting with Eli Lilly's more optimistic stance on the coverage being a significant boost [4]

Core Viewpoint - Gilead Sciences, Inc. reported strong fourth-quarter results for 2025, with adjusted earnings per share (EPS) of $1.86, exceeding estimates, while total revenues of $7.9 billion also surpassed expectations, driven by growth in HIV and Liver Disease drugs [1][4][6]. Financial Performance - Adjusted EPS for Q4 2025 was $1.86, beating the Zacks Consensus Estimate of $1.83, but down from $1.90 a year ago due to higher acquired IPR&D expenses [1][6]. - Total revenues reached $7.9 billion, a 5% increase year over year, surpassing the Zacks Consensus Estimate of $7.6 billion [1][4]. - Product sales increased by 5% year over year to $7.9 billion, with HIV product sales growing 6% to $5.8 billion [4][5]. Product Sales Breakdown - Biktarvy sales rose 5% year over year to $4 billion, capturing over 52% of the U.S. HIV treatment market [5][6]. - Descovy sales surged 33% year over year to $819 million, driven by increased demand for HIV prevention [6][7]. - Liver Disease portfolio sales increased 17% to $844 million, exceeding estimates, primarily due to demand for Livdelzi [8]. - Veklury sales fell 37% to $212 million, attributed to lower COVID-19 hospitalization rates [8]. Cost and Expenses - Adjusted product gross margin was 86.8%, slightly up from 86.7% year over year [11]. - Research and development expenses remained flat at $1.6 billion, while SG&A expenses decreased to $1.7 billion from $1.9 billion [11][12]. 2025 and 2026 Guidance - For 2025, revenues rose 2% year over year to $29.4 billion, exceeding estimates, with adjusted EPS increasing to $8.15 from $4.62 in 2024 [13]. - Gilead expects 2026 product sales between $29.6 billion and $30 billion, with adjusted EPS projected in the range of $8.45-$8.85 [14][15]. Pipeline and Regulatory Updates - Positive phase III results for the investigational regimen of bictegravir and lenacapavir were reported, with a potential launch targeted for the second half of the year [16][23]. - Gilead has discontinued several studies based on recommendations from independent committees, including the phase III STAR-221 study [18][19]. Market Position and Competitive Landscape - Gilead's HIV business exceeded management's growth target, driven by strong performances from Biktarvy and Descovy, despite competitive pressures [21][22]. - The company anticipates continued competitive pressures in cell therapies and expects to face headwinds from U.S. government drug pricing agreements [24][27].

Amazon is enhancing its health-related offerings by expanding the geographic range of its same-day prescription delivery service and by launching a beta feature that helps patients understand their lab results.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Complete the form to unlock this article and enjoy unlimited free access to all PYM ...

Core Insights - Exelixis, Inc. (EXEL) reported better-than-expected fourth-quarter results for 2025, with adjusted earnings per share (EPS) of 94 cents, surpassing the Zacks Consensus Estimate of 77 cents and up from 55 cents in the same quarter last year [1][2][6] - The company achieved net revenues of $598.7 million, exceeding the Zacks Consensus Estimate of $585 million, representing a year-over-year increase of 5.6% [2][4] - Despite the positive results, Exelixis' stock experienced a decline in pre-market trading following the earnings announcement [2] Financial Performance - The growth in net revenues was primarily driven by higher product sales, with net product revenues reaching $546.6 million, a 6% increase year over year [4] - Cabometyx (cabozantinib) generated revenues of $544.7 million, slightly missing the Zacks Consensus Estimate of $554 million but marginally exceeding internal estimates [5][6] - Collaboration revenues totaled $52.1 million, reflecting a 1% year-over-year increase, mainly due to higher royalty revenues from cabozantinib sales outside the U.S. [8] Operating Expenses - Research and development expenses, including stock-based compensation, decreased by 14.4% year over year to $213.2 million, attributed to lower clinical trial costs [9] - Selling, general, and administrative expenses fell by 8% year over year to $123 million, primarily due to reductions in stock-based compensation and personnel costs [9] Share Repurchase Program - During the quarter, Exelixis repurchased $264.5 million in shares, completing a $500 million share repurchase program authorized in February 2025 [10] - Since the initiation of its first share repurchase program in March 2023, the company has repurchased a total of $2.16 billion in common stock [10] 2025 Results and 2026 Guidance - For 2025, Exelixis reported revenues of approximately $2.32 billion, a 7% increase from 2024, with adjusted EPS of $3.08, up from $2 in 2024 [11] - The company expects total revenues for 2026 to be between $2.525 billion and $2.625 billion, with net product revenues projected to be in the range of $2.325 billion to $2.425 billion [12] Pipeline and Regulatory Updates - Exelixis is developing zanzalintinib, a next-generation oral investigational tyrosine kinase inhibitor, with an NDA accepted by the FDA for previously treated metastatic colorectal cancer [14][15] - The company is also advancing several phase I assets and has two new investigational new drug filings planned for 2026 [21][22] Market Position and Future Outlook - Cabometyx remains a leading TKI monotherapy for renal cell carcinoma (RCC) and is gaining traction in the neuroendocrine tumor market [23] - The strong uptake of Cabometyx in the newly approved NET indication is expected to drive future sales growth [24] - The potential approval of zanzalintinib is viewed as a significant catalyst for Exelixis' oncology pipeline, with management expanding sales infrastructure to support growth [24][25]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. SIRIO PHARMA CO., LTD. 仙樂健康科技股份有限公司 (A joint stock company incorporated in the People's Republic of China with limited liability) WARNING The publ ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. 深圳信立泰藥業股份有限公司 (the "Company") (A joint stock company incorporated in th ...